CA3111915A1 - Therapeutic uses of atomic quantum clusters - Google Patents

Therapeutic uses of atomic quantum clusters Download PDF

Info

Publication number
CA3111915A1
CA3111915A1 CA3111915A CA3111915A CA3111915A1 CA 3111915 A1 CA3111915 A1 CA 3111915A1 CA 3111915 A CA3111915 A CA 3111915A CA 3111915 A CA3111915 A CA 3111915A CA 3111915 A1 CA3111915 A1 CA 3111915A1
Authority
CA
Canada
Prior art keywords
composition
aqcs
cancer
metal atoms
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3111915A
Other languages
English (en)
French (fr)
Inventor
David Buceta Fernandez
Fernando Dominguez Puente
Manuel Arturo Lopez Quintela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Santiago de Compostela
Nanogap Sub NM Powder SA
Original Assignee
University of Santiago de Compostela
Nanogap Sub NM Powder SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Santiago de Compostela, Nanogap Sub NM Powder SA filed Critical University of Santiago de Compostela
Publication of CA3111915A1 publication Critical patent/CA3111915A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C5/00—Alloys based on noble metals
    • C22C5/06—Alloys based on silver
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/12—Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/20—Electrolytic production, recovery or refining of metals by electrolysis of solutions of noble metals
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C5/00—Electrolytic production, recovery or refining of metal powders or porous metal masses
    • C25C5/02—Electrolytic production, recovery or refining of metal powders or porous metal masses from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2202/00—Treatment under specific physical conditions
    • B22F2202/11—Use of irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Nanotechnology (AREA)
  • Electrochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3111915A 2018-09-26 2019-09-25 Therapeutic uses of atomic quantum clusters Pending CA3111915A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18196959.3 2018-09-26
EP18196963.5 2018-09-26
EP18196963 2018-09-26
EP18196959 2018-09-26
PCT/ES2019/070637 WO2020065115A2 (es) 2018-09-26 2019-09-25 Usos terapéuticos de clústeres cuánticos atómicos

Publications (1)

Publication Number Publication Date
CA3111915A1 true CA3111915A1 (en) 2020-04-02

Family

ID=68342935

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3111915A Pending CA3111915A1 (en) 2018-09-26 2019-09-25 Therapeutic uses of atomic quantum clusters

Country Status (11)

Country Link
US (1) US20220031740A1 (enExample)
EP (1) EP3862109A2 (enExample)
JP (2) JP2022502450A (enExample)
KR (1) KR20210086606A (enExample)
CN (2) CN120053481A (enExample)
AU (2) AU2019349780B2 (enExample)
BR (1) BR112021005775A2 (enExample)
CA (1) CA3111915A1 (enExample)
IL (1) IL281663A (enExample)
MX (1) MX2021003566A (enExample)
WO (1) WO2020065115A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1303421C (zh) * 2004-03-24 2007-03-07 南京大学 一种用于有机氯、有机磷农药分析的同步净化提取方法
JP7595087B2 (ja) * 2020-05-09 2024-12-05 深▲セン▼深見医薬科技有限公司 非定型抗精神病薬による副作用の治療
CN111906328B (zh) * 2020-08-11 2022-10-25 苏州大学 一种177Lu标记的金纳米团簇及其制备方法和应用
JP2025034223A (ja) * 2023-08-30 2025-03-13 株式会社ハイレックスコーポレーション ワイヤロープ
WO2026124952A1 (fr) * 2024-12-13 2026-06-18 Saint-Gobain Glass France Substrat verrier antimicrobien

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277531B2 (es) * 2005-08-03 2008-07-16 Universidad De Santiago De Compostela Procedimiento para la obtencion de clusteres cuanticos atomicos.
CN101113046A (zh) * 2006-07-25 2008-01-30 安正五 纳米胶体银水的制备方法
ES2319064B1 (es) * 2007-10-05 2010-02-15 Universidad De Santiago De Compostela Uso de clusteres cuanticos atomicos (aqcs) como antimicrobianos y biocidas.
CN101486733B (zh) * 2009-03-09 2011-05-25 华南师范大学 含氧桥双核钼原子簇化合物及其制备方法和用途
EP2457572A1 (en) * 2010-11-05 2012-05-30 Universidade De Santiago De Compostela Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases
WO2015015301A2 (en) * 2013-07-31 2015-02-05 Palama Ilaria El Cancer therapy with silver nanoparticles
KR102975187B1 (ko) * 2018-06-12 2026-06-08 나노갭 서브-엔엠-파우더, 쏘시에다드 아노니마 정제된 원자 양자 클러스터를 제조하는 방법

Also Published As

Publication number Publication date
BR112021005775A2 (pt) 2021-06-29
KR20210086606A (ko) 2021-07-08
WO2020065115A3 (es) 2020-05-22
JP2022502450A (ja) 2022-01-11
EP3862109A2 (en) 2021-08-11
AU2025238114A1 (en) 2025-10-23
JP2024122998A (ja) 2024-09-10
AU2019349780A1 (en) 2021-03-25
CN120053481A (zh) 2025-05-30
WO2020065115A2 (es) 2020-04-02
US20220031740A1 (en) 2022-02-03
MX2021003566A (es) 2021-08-16
IL281663A (en) 2021-05-31
CN113179632A (zh) 2021-07-27
AU2019349780B2 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
AU2019349780B2 (en) Therapeutic uses of atomic quantum clusters
Mao et al. Cuproptosis: mechanisms and nanotherapeutic strategies in cancer and beyond
ES2853973T3 (es) Uso de DNQ o DNQ-87 en combinación con un inhibidor de PARP1 para el tratamiento del cáncer
Brabec et al. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt (NH3) 2malSAHA–2H)]
HK1208365A1 (en) Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
US20220265592A1 (en) Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
EP1677740A2 (en) Methods and compositions for treating cancer
US20060078494A1 (en) Use of inhibitors of 24-hydroxylase in the treatment of cancer
EP3386546B1 (en) Combination for the effective treatment of metastatic cancer in patients
CN102014891A (zh) 增加癌症患者存活时间的化合物的组合物和使用方法
HK40057518A (en) Therapeutic uses of atomic quantum clusters
US20220396794A1 (en) APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR)
US20260084978A1 (en) Process for producing atomic quantum clusters derivatives
Wang et al. Repurposing antihistamine to chemotherapy via a molecular delivery platform co-targeting mitochondria and endoplasmic reticulum
Ballerini et al. Gasotransmitters bridging tumor biology and immunity: from pathophysiological insights to therapeutic potential
JP7461894B2 (ja) 精製された原子量子クラスターの調製方法
WO2022087173A1 (en) Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof
EP4541425A2 (en) Treating cancers with combinations of acylfulvenes with ibrutinib or bortezomib
US20180104336A1 (en) Method of Increasing Radiation Sensitivity of Tumor Cells
Rizza The Roles of the Denitrosylase GSNOR in Tumor Progression.
Millard Discovery of novel small molecules targeting cancer cell metabolism

Legal Events

Date Code Title Description
P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240904

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240905

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240917

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240917

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240917

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241113

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241202

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241202

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250414

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250612

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250918

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250918

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20251002

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251022

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260220

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260224

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260224